Asieris Pharmaceuticals Partners with Theramex for CEVIRA® to Advance Non-Surgical Treatment in Europe
In a significant move for women's health, Asieris Pharmaceuticals has formed an exclusive licensing agreement with Theramex for their innovative photodynamic therapy product CEVIRA® (APL-1702). This agreement will cover European countries as well as Australia, New Zealand, and Turkey, while Asieris retains rights for the rest of the globe. The deal, which could total more than $250 million, includes an upfront payment of $15 million, alongside stipulations for regulatory and commercial milestone payments, as well as tiered royalties.
CEVIRA® is a groundbreaking combination of drug and device aimed at offering a non-surgical option for treating cervical precancerous lesions stemming from HPV infections. With a focus on cervical intraepithelial neoplasia, the product is noted for its potential to be administered in an office setting by healthcare professionals, making it a well-suited alternative for women who might otherwise require surgical procedures. This approach not only preserves cervical tissues but also addresses a significant unmet medical need for non-surgical treatments around the world.
The licensing agreement with Theramex is contingent on several essential conditions, including the signing of a supply agreement, successful audits at CEVIRA® manufacturing sites, and ensuring alignment with upstream licensing agreements. Additionally, there will be clarification needed regarding the product's clinical value assessment with the European Commission. The deal reflects a robust financial commitment, marking it as a pivotal partnership in the biopharmaceutical industry.
This arrangement follows Asieris' recent milestones, including the approval of CEVIRA® by China's National Medical Products Administration in March 2026 as the first non-invasive therapy for cervical precancerous lesions. This noteworthy achievement serves as a launching pad for global commercialization efforts and enhances the drug's credibility in markets beyond Asia.
Founded in March 2010, Asieris Pharmaceuticals is dedicated to the advancement of innovative therapies targeting genitourinary tumors and women's health. The company is focused on integrating research, development, manufacturing, and commercialization of its specialized products. By leveraging both in-house research and strategic collaborations, Asieris aims to deliver first-in-class drugs that fulfill unmet medical needs, building a comprehensive portfolio in the processes it targets.
Theramex is a reputable global specialty pharmaceutical company with a strong commitment to women’s health. Operating in over 50 countries, the company supports women through various life stages by providing products that cater to contraception, fertility, menopause, osteoporosis, and uterine health. Theramex’s partnership with Asieris emphasizes its dedication to enhancing healthcare solutions for women worldwide, delivering innovative treatments designed to improve their lives.
This strategic collaboration sets the stage for the future of non-surgical treatments in the realm of gynecology, as Asieris and Theramex look to redefine the management of cervical precancerous lesions. Stakeholders within the healthcare community will be watching closely as both companies pave the way for increasing access to this pivotal treatment, which could have profound implications for women's health globally. As they move forward, potential hurdles surrounding regulatory approvals and market acceptance will be critical factors in the successful rollout of CEVIRA® in the aforementioned regions. This partnership not only signifies a commitment to innovation but also embodies a broader mission to elevate women's health standards across diverse markets.
Background of CEVIRA®
CEVIRA® is a groundbreaking combination of drug and device aimed at offering a non-surgical option for treating cervical precancerous lesions stemming from HPV infections. With a focus on cervical intraepithelial neoplasia, the product is noted for its potential to be administered in an office setting by healthcare professionals, making it a well-suited alternative for women who might otherwise require surgical procedures. This approach not only preserves cervical tissues but also addresses a significant unmet medical need for non-surgical treatments around the world.
Financial Terms
The licensing agreement with Theramex is contingent on several essential conditions, including the signing of a supply agreement, successful audits at CEVIRA® manufacturing sites, and ensuring alignment with upstream licensing agreements. Additionally, there will be clarification needed regarding the product's clinical value assessment with the European Commission. The deal reflects a robust financial commitment, marking it as a pivotal partnership in the biopharmaceutical industry.
This arrangement follows Asieris' recent milestones, including the approval of CEVIRA® by China's National Medical Products Administration in March 2026 as the first non-invasive therapy for cervical precancerous lesions. This noteworthy achievement serves as a launching pad for global commercialization efforts and enhances the drug's credibility in markets beyond Asia.
About Asieris Pharmaceuticals
Founded in March 2010, Asieris Pharmaceuticals is dedicated to the advancement of innovative therapies targeting genitourinary tumors and women's health. The company is focused on integrating research, development, manufacturing, and commercialization of its specialized products. By leveraging both in-house research and strategic collaborations, Asieris aims to deliver first-in-class drugs that fulfill unmet medical needs, building a comprehensive portfolio in the processes it targets.
About Theramex
Theramex is a reputable global specialty pharmaceutical company with a strong commitment to women’s health. Operating in over 50 countries, the company supports women through various life stages by providing products that cater to contraception, fertility, menopause, osteoporosis, and uterine health. Theramex’s partnership with Asieris emphasizes its dedication to enhancing healthcare solutions for women worldwide, delivering innovative treatments designed to improve their lives.
Looking Ahead
This strategic collaboration sets the stage for the future of non-surgical treatments in the realm of gynecology, as Asieris and Theramex look to redefine the management of cervical precancerous lesions. Stakeholders within the healthcare community will be watching closely as both companies pave the way for increasing access to this pivotal treatment, which could have profound implications for women's health globally. As they move forward, potential hurdles surrounding regulatory approvals and market acceptance will be critical factors in the successful rollout of CEVIRA® in the aforementioned regions. This partnership not only signifies a commitment to innovation but also embodies a broader mission to elevate women's health standards across diverse markets.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.